-
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on ...资讯2024-10-09
最热